Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retrovirus vectors: toward the plentivirus?

Christopher Baum1, Axel Schambach, Jens Bohne

  • 1Department of Experimental Hematology, Hannover Medical School, D-30625 Hannover, Germany. baum.christopher@mh-hannover.de

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Capsid-engineered AAV vector overcomes a key intracellular barrier and efficiently transduces spiral ganglion neurons in adult mice.

Molecular therapy. Advances·2026
Same author

Editorial: Community Series in Engineered Immune Cells in Cancer Immunotherapy (EICCI), volume II.

Frontiers in immunology·2026
Same author

Ex vivo long-term expansion of human hematopoietic stem and progenitor cells as a tool for modeling vector integration sites and clonality.

Journal of translational medicine·2026
Same author

SAGA-Q: Gene Expression Differences Enable Detection of Retroviral Vectors with Mutagenic Potential.

Human gene therapy·2026
Same author

Therapeutic antibody delivery: vector tools to boost efficacy and affordability.

Frontiers in immunology·2026
Same author

Improved Antitumor Activity of Interleukin-12-Secreting Chimeric Antigen Receptor T Cells Targeting CD176 across Different Carcinomas.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2026
Same journal

Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Endothelial injury with capillary leak: A final common pathway in acute AAV toxicity?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Long-term functional synaptic integration of genome-edited retinal organoids in a primate model of macular degeneration.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Nox1/4 inhibitor Setanaxib treatment ameliorates cardiac function in mouse models of Duchenne Muscular Dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

HSP90α-USP7-DNMT1 Axis Drives Hepatocellular Carcinoma Recurrence After Microwave Ablation by Disrupting ACSS3-Mediated Propionate Metabolism.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Cell-penetrating asymmetric siRNA targeting MyD88 suppresses inflammasome-driven ocular degeneration and angiogenesis.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
See all related articles

Researchers propose developing novel hybrid retroviral vectors by combining features from different retroviruses. These advanced gene therapy tools aim for enhanced efficacy and safety through improved vector design and nonretroviral components.

Area of Science:

  • Gene therapy
  • Molecular biology
  • Virology

Background:

  • Retroviral vectors (gammaretroviruses, lentiviruses, spumaviruses) are established tools for stable gene transfer.
  • The Retroviridae family possesses diverse life cycle features exploitable for specialized gene therapy applications.

Purpose of the Study:

  • To conceptualize novel hybrid retroviral vectors by integrating beneficial traits from various retroviruses.
  • To outline key features for an improved retroviral vector with enhanced therapeutic efficacy and biosafety.

Main Methods:

  • Exploiting natural differences in retroviral life cycles for vector design.
  • Envisioning the combination of specific features like efficient packaging, serum resistance, and targeted gene delivery.
  • Considering the integration of nonretroviral components into vector systems.

Related Experiment Videos

Main Results:

  • A hybrid vector design incorporating features such as noncytopathic packaging, serum resistance, and cell-specific pseudotyping is proposed.
  • The envisioned vector aims for high-fidelity reverse transcription, unrestricted transport, insulated expression, chromosomal targeting, and regulated transgene expression.
  • The combination of these features is expected to yield increased therapeutic efficacy and an improved biosafety profile.

Conclusions:

  • Hybrid retroviral vectors hold significant promise for advancing gene therapy.
  • Achieving optimal vector performance may necessitate the incorporation of nonretroviral elements.
  • Future vector development should focus on combining desirable retroviral and nonretroviral components for enhanced safety and efficacy.